Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy

American Journal of Hematology

Volumn 89, Issue 4, 2014, Pages 395-398

  Jabbour, Elias ^a   Daver, Naval ^a   Champlin, Richard ^a   Mathisen, Michael ^a   Oran, Betul ^a   Ciurea, Stefan ^a   Khouri, Issa ^a   Cornelison, A Megan ^a   Ghanem, Hady ^a   Cardenas Turanzas, Marylou ^a   Popat, Uday ^a   Ravandi, Farhad ^a   Giralt, Sergio ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   de Lima, Marcos ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; ALLOGRAFTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CYTARABINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84897388751     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23655     Document Type: Article

References (17)

1. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000;14:476-479.
2. Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010;116:5818-5823; quiz 6153.
3. Stanisic S, Kalaycio M. Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2002;2:287-295.
4. Revesz D, Chelghoum Y, Le QH, et al. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: Analysis of prognostic factors. Ann Hematol 2003;82:684-690.
5. Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol: Off J Am Soc Clin Oncol 2010;28:3730-3738.
6. Zander AR, Dicke KA, Keating M, et al. Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy. Cancer 1985;56:1374-1379.
7. Oyekunle AA, Kroger N, Zabelina T, et al. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: A long-term follow-up. Bone Marrow Transpl 2006;37:45-50.
8. Forman SJ, Schmidt GM, Nademanee AP, et al. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Clin Oncol: Off J Am Soc Clin Oncol 1991;9:1570-1574.
9. Mehta J, Powles R, Horton C, et al. Bone marrow transplantation for primary refractory acute leukaemia. Bone Marrow Transpl 1994;14:415-418.
10. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106:1154-1163.
11. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710-1717.
12. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer 2006;107:116-124.
13. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-4124.
14. Armistead PM, de Lima M, Pierce S, et al. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transpl: J Am Soc Blood Marrow Transpl 2009;15:1431-1438.
15. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007;109:1395-1400.
16. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009;115:1899-1905.
17. de Lima M, Giralt S, Thall PF, et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study. Cancer 2010;116:5420-5431.